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Summary 
Effects of neurotensin (NT) on gallbladder contraction were examined both in vivo and 
in vitro. Cholecystokinin-octapeptide (CCK-8) was used to evaluate the methods used in this 
study and to compare the action of NT on the gallbladder. In In vivo studies, gallbladder con-
traction was monitored by strain gauge force transducers implanted on the surface of the dog 
gallbladder. Bolus intravenous (IV) injection of :¥T at doses of 20 and 40 ng/kg caused 
gallbladder contraction of similar of magnitudes in terms of contractile force, while CCK-8 
caused contraction dose-dependently. Continuous IV infusion of NT at doses of 250 and 
500 ng/kg/hr, which resulted in an elevation of blood levels of :-.JT comparable with those achieved 
by endogenous release, induced a transient gallbladder contraction. Both maximum contractile 
force and onset time of contraction were similar to both does of NT. In contrast, CCK-8 induced 
gallbladder contraction was sustained during infusion of CCK-8 and was dose-dependent for 
both maximum contractile force and onset time of contraction. :¥T-induced gallbladder con-
traction was completely abolished by atropine treatment. In In vitro studies of longitudinal 
rabbit gallbladder muscle strips, NT was ineffective, while CCK-8 caused a dose-dependent 
contraction. The present study shows that :-.;T can stimulate gallbladder contraction in the 
dog via cholinergic pathways. 
Introduction 
'.¥eurotensin (NT) was discovered by CARRAWAY and LEEMAN in 19738> as a by product 
during purification of substance P from bovine hypothalamus. It was found to produce vasodi-
lation and hypotension when injected into rats. The sequence of '.¥IT (pGlu Leu-Tyr-Glu-
Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-OH; MW= 1673), its synthesis and a specific radioim-
munoassay were reported shortly thereafter9,10つ11)
Although initially found in the brain, over 90 percent of NT in the body occurs outside the 
central nervous system, largely in the small intestine12>. There are detectable levels in the 
esophagus, stomach, duodenum, and colon. However、thevast majority of :¥T is found in the 
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small intestine‘with the greatest amount in the ileum of rats, dogs14‘15' 21‘26,42> and humans11,21>. 
In the small intestine of man and animals‘＞.＇T exists not in the nervous system but in mucosa! 
cells (called N cels), which are typical gut endocrine cell-type with basal granules and microvilli 
reaching into the gut lumen. From these morphological characteristics of the N cels, it is thought 
that :'¥Tis released into the blood stream by suitable luminal stimulants (such as fatty nutrients3I>). 
Gastrointestinal effects of NT include mesenteric vasodilation30>, inhibition of gastric acid 
secretion3人間， alterationof gastrointestinal motility29,32l and pancreatic exocrine secretion22, 
35, 36）ー Theeffect of NT on gallbladder function has been reported to increase intragallbladder 
pressure in chronic fistula dogs3的、 buteffects on gallbladder motility are not elucidated. The 
purpose of this study was to examine the effect of NT on gallbladder contraction both in vivo and 
m vitro. 
Materials and恥1ethods
In vivo study 
Five mongrel dogs of both sexes (18-22 kg) were prepared with strain-gauge force 
transducers18,19> (provided by Dr. ZEN IToH, :Vlaebashi, Japan). Under secobarbital anesthesia 
(30 mg/kg body weight, IV), force transducers were sutured on the midportion of the serosal 
surface of the gallbladder with a 4 0 atraumatic needle in a direction to detect the contractions of 
the circular muscle. The lead wires from this transducer were directed to the hepatic hilus 
along the cystic duct and lightly sutured on the gallbladder surface at approximately 2 cm distal 
from the sensor. In addition, a bipolar electrode was implanted onto the surface of the duode-
num. The lead wires were exteriorized at the right subcostal margin, passed through a sub-
cutaneous tunnel, pulled out through a stab wound made between the scapulae, and sutured 
to the skin. After the operation, small connectors were attached to the lead wires and the dog 
was fitted with a canvas jacket to protect the wire terminals. 
Studies were started three weeks after the above operations. The dogs were fasted overnight 
for 18 hours with free access to water before each experiment. During each experiment, the dogs 
were placed in PAVLOV stands and the canvas jackets were removed. The contractile activity of 
the gallbladder and myoelectric activity of the duodenum were recorded with a Beckman R-611 
Dynograph (Beckman Instruments Inc., Palo Alto, CA). The duodenal electrode was used to 
monitor electrical activity in the duodenum. While the gallbladder and duodenum were in the 
quiescent phase, a bolus injection of :'¥T (10, 20 or 40 ng/kg), cholecystokinin-8 (CCK 8) (0.5, 
1, 2, 3, 4 or 5 ng/kg), a continuous infusion of NT (125, 250, 500 or 1,000 ng/kg/hr) or CCK-8 
(25, 50 or 100 ng/kg/hr) was given intravenously. 
The continuous infusion of :¥T and CCK 8 was repeated during IV atropine (InvenexR, 
The Dexter Corp., Chagrin Falls, Ohio) treatment (25 ng/kg bolus, followed by 20 ng/kg/hr 
infusion). 
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In vitro study 
Gallbladder contraction was measured by a modification 23> of the bioassay for CCK de-
scribed earlier by BERRY and FLOWER4>. Longitudinal gallbladder strips (3-4 cm long, 0.3 cm 
wide) were obtained from fiv巴24-hourfasted .'¥ ew Zealand white rabbits (2-3 kg). The gall-
bladder strip was placed in an organ bath containing 20 mg of Krebs solution. Tension changes 
were monitored by an isometric force-displacement transducer (UC2, Gould討tathamInstru-
ments Inc., Oxnard, CA) and recorded with a Beckman R-611 Dynograph. :VIeasurements 
were started after a 2-3 hour period of stabilization. The transducers were set to zero. 
Gallbladder strip tension in response to CCK-8 (1 ng/ml) as a control and '.'¥T (5, 10, 20 or 40 ng/ 
ml) were tested. 
Solutions 
:¥T (Bachem, Torrance, CA) and CCK 8 (Bachem, Torrance, ＜‘＇A) were dissolved in a con-
centration of 1 mg/ml in distilled water containing 0.1 % bovine serum albumin (BSA) (Sigma 
Chemical Co., St. Louis, :¥IO); they were divided into aliquots and stored at -20°C until used. 
Measurement and Analysis of Data 
The contractile force of the gallbladder in vivo was measured in grams. In vitro tension 
changes of the gallbladder strip were measured in milligrams. Values are expressed as mean 
士SE:¥!. A P value < 0.05 was considered statistically significant. 
Results 
In vivo study 
IV bolus administration of CCK-8 (0.5, 1, 2『3‘4‘5ng/kg) caused a dose related contraction 
of the gallbladder (Fig. 1, upper panel). IV bolus administration of >JT (10, 20, 40 ng/kg) 
induced gallbladder contraction (Fig. 1、lowerpanel). The minimum dose of :¥"T to cause 
gallbladder contraction was 20 ng/kg. Contractile force obtained by 20 ng/kg (12 pmol/kg) 
and 40 ng/kg (24 pmol/kg) of :¥"T were almost the same、comparableto that obtained by CCK-8 
at a dose of 2時／kg(1.8 pmol/kg). Continuous infusion of :¥"T (250‘500, 1,000 ng/kg/hr) 
caused gallbladder contraction. The response of the gallbladder was not dose-related and 
transient (Fig. 2）ー Atropine(25 ng/kg bolus, 20 ng/kg/hr infusion) completely abolished the 
efect of NT on gallbladder contraction (Fig. 2, lower right panel). ＜‘ontinuous infusion of 
CCK 8 (25, 50, 100 ng/kg/hr) caused gallbladder contraction in a dose-dependent manner (Fig. 
3). The gallbladder contraction induced by CC K-8 was sustained during the infusion and 
returned quickly to baseline after cessation of th巴 infusionof CC K 8. Atropine diminished 
gallbladder contractile force (Fig. 3, lower right panel). 
Summarized data calculated as contractile force at maximum contraction and onset time of 
contraction during NT (250, 500 ng/kg/hr) or CCK 8 infusion (25. 50 ng/kg/hr) are shown in 
Table 1. XT stimulated gallbladder contraction, but the contractile force or the onset time of 
gallbladder contraction was not significantlyアchangedby increasing the dose of :¥"T from 250 ng/ 
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Effects of a bolus intravenous injection of CCK 8 (upper panel) and NT (lower panel) 
recorded from two different dogs. 
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TIME INTERVALS (10 min) 
Fig. 2. Effects of continuous intravenous infusion of NT at doses of 250, 500 and lOOOng/kg/ 
hr (upper panels and lower left panel), and at a dose of lOOOng/kg/hr under the 
treatment of atropine (25 ng/kg bolus followed by 20 ng/kg/hr infusion) (lower right 
panel). 
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TIME INTERVALS (10 min) 
Fig. 3. Effects of continuous intravenous infusion of CCK-8 at doses of 25, 50 and lOOng/kg/ 
hr (upper panels and lower left panel), and at a dose of lOOng/kg/hr under the 
treatment of atropine (25ng/kg bolus followed by 20ng/kg/hr infu日on)(lower right 
panel). 
kg/hr to 500 時／｝叫hr. Increasing the dose of CCK-8 from 25 ng/kg/hr to 50碍／kg/hrsignifi-
cantly increased the contractile force of the gallbladder and significantly decreased the onset 
time of gallbladder contraction. Contractile force at maximum concentration obtained by 
CCK-8 at doses of 25 and 50 ng/kg/hr was significantly larger and onset time of contraction was 
signi自cantlyshorter than those obtained by :'.'JT at 250 or 500 ng/kg/hr. 
In vitro study 
Tension in gallbladder strips increased uniformly in response to C℃K 8 but NT had no 
efects in this system (data not shown). 
Table 1. Summarized data of effects of NT and CCK-8 on contractile 
force at maximum contraction (gram) and onset time of con-
traction (minutes）・＊＝P<O.05 versus NT 250 or 500ng/kg/hr 
ム＝Pく0.05 versus CCK-8 25ng/kg/hr. 
Dose Contractile Force at Onset Time of 





250 5 6.6士1.2 6.2土0.6
500 5 7. 6±0. 4 5.8土1.1
25 5 9.3土0.8* 2. 4±0. 4* 
50 5 12.5土0.7*/ 1. 5土0.3＊ム
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Discussion 
The present study shows that NT, a gut peptide, stimulates gallbladder contraction in the 
dog in vivo. Contractile effects of NT were transient and were not sustained during the con-
tinuous infusion of :-JT. The magnitude of contractile force was not dose-dependent. Further-
more, atropine completely abolished the stimulatory effect of NT on gallbladder contraction. 
These data, together with the in vitro study, in which NT had no effect on rabbit gallbladder 
strips, indicate that the action of NT on the gallbladder is apparently mediated by cholinergic 
pathways. 
CCK, a well established gut peptide. causes gallbladder contraction2, 40l by a direct action 
at the gallbladder muscle37, 43l. CCK 8 was used as a control not only to compare with NT but 
also to insure the accuracy of the methods engaged in this study. Thus, as it was reported39l, 
gallbladder contractions induced by CCK-8 in this study were found to cause dose-dependent 
contractions which were tonic and remained at a constant level as long as CCK-8 was infused 
intravenously. Atropine diminished gallbladder contractions induced by CCK-8. Myoelectric 
activity of the duodenum was monitored by a bipolar electrode in the duodenal muscle to avoid 
periodic contractions of the gallbladder which occur in close association with the interdigestive 
imm1gratmg contraction 20>. 
In the present study, bolus injection of different doses of NT did not change the magnitude of 
contractile force. SAKAMOTO et al.3> reported that IV bolus injection of NT caused an elevation 
of gallbladder pressure and atropine decreased gallbladder pressure induced by NT in chronic 
dogs with gallbladder fistulas. They also reported that NT increased gallbladder pressure in 
a dose-dependent manner and NT was approximately 1 : 50as potent as CCK-8, on a molar basis. 
In direct measurements of muslce contraction, NT-induced gallbladder contractions were not 
altered by different doses of l¥T. This might be due to the di百erentexperimental methods or to 
gallbladder pressure which is affected by many factors, such as sphincter of ODDI, cystic duct 
and so on. 
Furthermore, previous studies a so made use of pharmacologic doses of NT, since they used 
large amounts of NT (doses of 0 25, 0.5, 1.0 and 2.0 uμ,/kg as a bolus injection were tested). The 
doses of NT used in this study (as a bolus injection) were much les, but these doses are stil 
considered pharmacological since we did not determine whether blood levels of circulating NT 
obtained by bolus injection of NT exceeded physiological blood levels of NT. On the other hand, 
continuous IV infusions of NT, at doses of 250 and 500 ng/kg/hr, were considered to be physio-
logic, since blood levels of NT obtained by these doses were comparable to those achieved by 
endogenously released NT in response to intraduodenal perfusion of Lipomul at a dose of 
2 g/kg/hr34>. 
NT-induced gallbladder contractions in vitro were not observed, indicating that the action of 
:-.JT on the gallbladder is not directly at the gallbladder muscle. However, it might exert its 
actions at sites remote from the gallbladder. The same observation was reported for motilin 
which caused a dose-dependent contraction of the gallbladder in conscious pigs1>. However, 
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motilin had no effect on the gallbladder muscle in vitroas人 Pancreaticpolypeptide which caused 
gallbladder relaxation 16> in vivo did not have any effects in vitro2B>. 
Surprisingly, infusion of NT in normal human volunteers caused gallbladder relaxation 
assessed by ultrasonography41>. The mechanism of this effect is not known. It seems di伍cult
to attribute this to species differences. メTcan release PP6,;, 24>, which can relax the gallbladder, 
or '.¥T can affect norepinephrine which inhibits both vagal and field-stimulated responses by 
actions onαγadrenergic receptors on pre-and post-ganglionic cholinergic neuronsla> Tnus, 
further studies are needed to understand better the effects of ~Ton gallbladder motility. 
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理的条件下で記録した. NT (20および 40ng/kgJの
急速静注により胆嚢収縮がみとめられたが収縮の強さ
は投与量により変化しなかった.CCK-8 の急速静注
では，用量依存性に胆嚢収縮が発現した． また， NT
（お0および500ng/kg/hr）の持続注でも胆獲収縮は惹
起された．これらの投与量での NTの血中濃度は，
脂肪による NTの内因性放出時の血中濃度に匹敵す
るものであり，生理的範囲内の投与量であった．従っ
て，乙の胆嚢収縮は NTの生理的作用とみなすとと
ができる．しかしながら NTの血中への持続投与に
よる胆嚢収縮は一時的で，投与中でも収縮は持続しな
った．また投与量の違いICよっても最大収縮の強さ，
および収縮運動発現までの時聞に差はみられなかった．
アトロピンの投与下では NTによる胆嚢収縮はまっ
たくみられなかった．それに対して CCK-8の胆嚢収
縮作用は静脈内投与中ほぽ一定して持続し，乙の作用
lζは用量依存性の収縮力の増大と，作用発現時間の短
縮がみられた．一方，ウサギ胆嚢筋条片を用いた in
vitroでの実験では， NTの作用はみられなかったが，
CCK-8は用量依存性に胆嚢筋条件を収縮させた．
以上の結果から， NTにはその生理的作用のーっと
してイヌ胆嚢の収縮IC働くとと，そして乙の作用は迷
走神経を介している乙とが明らかとなった．
